# LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer

> **NCT05900986** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Integro Theranostics** · enrollment: 100 (estimated)

## Conditions studied

- Breast Cancer
- DCIS
- Invasive Duct Carcinoma of Breast

## Interventions

- **DRUG:** LS301-IT 0.025 mg/kg
- **DRUG:** LS301-IT 0.05 mg/kg
- **DRUG:** LS301-IT 0.075 mg/kg
- **DRUG:** LS301-IT 0.1 mg/kg

## Key facts

- **NCT ID:** NCT05900986
- **Lead sponsor:** Integro Theranostics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-07-14
- **Primary completion:** 2025-10-06
- **Final completion:** 2026-05
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05900986

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05900986, "LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05900986. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*